EMEA’s ‘Committee for Medicinal Products for Human Use’ (CHMP) on its July plenary meeting adopted
CHMP/EWP/1401/98 Rev. 1 (Guideline on the Investigation of Bioequivalence)
for a six-month public consultation period (i.e., until 31 January 2009).
A document (EMA/CHMP/EWP/26817/2010: 248 pages, 1.5MB) presenting comments received by EMA on the draft guideline was published on 10 February 2010.
document date 2008-08-21 | last update 2015-04-23